JP2019520852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520852A5 JP2019520852A5 JP2019514870A JP2019514870A JP2019520852A5 JP 2019520852 A5 JP2019520852 A5 JP 2019520852A5 JP 2019514870 A JP2019514870 A JP 2019514870A JP 2019514870 A JP2019514870 A JP 2019514870A JP 2019520852 A5 JP2019520852 A5 JP 2019520852A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- release system
- poi
- exosome
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 35
- 210000001808 Exosomes Anatomy 0.000 claims 8
- 229920000023 polynucleotide Polymers 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102100001475 ITGB2 Human genes 0.000 claims 4
- -1 Lamp2b Proteins 0.000 claims 4
- 102100019334 ITGA4 Human genes 0.000 claims 3
- 101710006711 ITGA4 Proteins 0.000 claims 3
- 101710006663 ITGB2 Proteins 0.000 claims 3
- 230000003213 activating Effects 0.000 claims 3
- 102000009899 alpha Karyopherins Human genes 0.000 claims 3
- 108010077099 alpha Karyopherins Proteins 0.000 claims 3
- 230000004807 localization Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003834 intracellular Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 claims 1
- 102100017224 AGRN Human genes 0.000 claims 1
- 101710004990 AGRN Proteins 0.000 claims 1
- 102100016549 ANPEP Human genes 0.000 claims 1
- 101710028178 ANPEP Proteins 0.000 claims 1
- 102100003269 CD151 Human genes 0.000 claims 1
- 101700010227 CD151 Proteins 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 108060001251 CD34 Proteins 0.000 claims 1
- 102100016492 CD34 Human genes 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 101700078950 CD44 Proteins 0.000 claims 1
- 102100003735 CD44 Human genes 0.000 claims 1
- 102100013078 CD47 Human genes 0.000 claims 1
- 101700033237 CD47 Proteins 0.000 claims 1
- 102100019284 CD53 Human genes 0.000 claims 1
- 101700029492 CD53 Proteins 0.000 claims 1
- 102100005827 CD63 Human genes 0.000 claims 1
- 101700052224 CD63 Proteins 0.000 claims 1
- 102100019450 CD81 Human genes 0.000 claims 1
- 101700062651 CD81 Proteins 0.000 claims 1
- 102100008204 CD82 Human genes 0.000 claims 1
- 101700087069 CD82 Proteins 0.000 claims 1
- 102100016531 CD9 Human genes 0.000 claims 1
- 101700017162 CD9 Proteins 0.000 claims 1
- 102100007693 COL6A1 Human genes 0.000 claims 1
- 101710040356 COL6A1 Proteins 0.000 claims 1
- 229920000033 CRISPR Polymers 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 101700044562 DLL1 Proteins 0.000 claims 1
- 102100013695 DLL1 Human genes 0.000 claims 1
- 101700018087 DLL4 Proteins 0.000 claims 1
- 102100019888 DLL4 Human genes 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 108091000102 DNA-Binding Proteins Proteins 0.000 claims 1
- 102000031025 DNA-Binding Proteins Human genes 0.000 claims 1
- 230000004568 DNA-binding Effects 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101700067237 FLOT1 Proteins 0.000 claims 1
- 102100011949 FLOT1 Human genes 0.000 claims 1
- 101700068361 FLOT2 Proteins 0.000 claims 1
- 102100005570 FLOT2 Human genes 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 101710037135 GAPC2 Proteins 0.000 claims 1
- 101710037116 GAPC3 Proteins 0.000 claims 1
- 101710025049 GAPDG Proteins 0.000 claims 1
- 101710008404 GAPDH Proteins 0.000 claims 1
- 102100006425 GAPDH Human genes 0.000 claims 1
- 108060003205 GRIA2 Proteins 0.000 claims 1
- 102100014480 GRIA2 Human genes 0.000 claims 1
- 108060003206 GRIA3 Proteins 0.000 claims 1
- 102100014479 GRIA3 Human genes 0.000 claims 1
- 102100018914 GYPA Human genes 0.000 claims 1
- 101710042158 GYPA Proteins 0.000 claims 1
- 101710010461 Gapdh1 Proteins 0.000 claims 1
- 102100012018 HSPG2 Human genes 0.000 claims 1
- 101700046483 HSPG2 Proteins 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 102100004115 ICAM1 Human genes 0.000 claims 1
- 101700051176 ICAM1 Proteins 0.000 claims 1
- 102100004114 ICAM2 Human genes 0.000 claims 1
- 101700035976 ICAM2 Proteins 0.000 claims 1
- 102100004110 ICAM3 Human genes 0.000 claims 1
- 101700014306 ICAM3 Proteins 0.000 claims 1
- 102100019336 ITGA2 Human genes 0.000 claims 1
- 101710006710 ITGA2 Proteins 0.000 claims 1
- 102100019332 ITGA2B Human genes 0.000 claims 1
- 101710044247 ITGA2B Proteins 0.000 claims 1
- 102100019335 ITGA3 Human genes 0.000 claims 1
- 101710006708 ITGA3 Proteins 0.000 claims 1
- 102100008588 ITGA5 Human genes 0.000 claims 1
- 101710006709 ITGA5 Proteins 0.000 claims 1
- 102100019442 ITGAL Human genes 0.000 claims 1
- 101710006573 ITGAL Proteins 0.000 claims 1
- 102100019441 ITGAM Human genes 0.000 claims 1
- 101710006572 ITGAM Proteins 0.000 claims 1
- 102100019438 ITGAV Human genes 0.000 claims 1
- 101710006691 ITGAV Proteins 0.000 claims 1
- 102100019437 ITGAX Human genes 0.000 claims 1
- 101710006689 ITGAX Proteins 0.000 claims 1
- 102100001477 ITGB3 Human genes 0.000 claims 1
- 101710006664 ITGB3 Proteins 0.000 claims 1
- 102100001473 ITGB4 Human genes 0.000 claims 1
- 101710006665 ITGB4 Proteins 0.000 claims 1
- 102100012521 ITGB5 Human genes 0.000 claims 1
- 101710006668 ITGB5 Proteins 0.000 claims 1
- 102100012520 ITGB6 Human genes 0.000 claims 1
- 101710006666 ITGB6 Proteins 0.000 claims 1
- 102100012517 ITGB7 Human genes 0.000 claims 1
- 101710006575 ITGB7 Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 102000012330 Integrases Human genes 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 claims 1
- 101700058295 JAG1 Proteins 0.000 claims 1
- 102100006542 JAG1 Human genes 0.000 claims 1
- 102100006540 JAG2 Human genes 0.000 claims 1
- 101700078190 JAG2 Proteins 0.000 claims 1
- 102100016985 KIT Human genes 0.000 claims 1
- 102100004400 L1CAM Human genes 0.000 claims 1
- 102100011553 LAMB1 Human genes 0.000 claims 1
- 101700062932 LAMB1 Proteins 0.000 claims 1
- 102100009092 LAMC1 Human genes 0.000 claims 1
- 102100005731 LGALS3BP Human genes 0.000 claims 1
- 101710024274 LGALS3BP Proteins 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 102100006993 MFGE8 Human genes 0.000 claims 1
- 101710028471 MFGE8 Proteins 0.000 claims 1
- 101710025050 MK0970 Proteins 0.000 claims 1
- 108090000301 Membrane transport proteins Proteins 0.000 claims 1
- 102000003939 Membrane transport proteins Human genes 0.000 claims 1
- 102100012131 NOTCH1 Human genes 0.000 claims 1
- 101710036042 NOTCH1 Proteins 0.000 claims 1
- 102100012126 NOTCH2 Human genes 0.000 claims 1
- 101710036046 NOTCH2 Proteins 0.000 claims 1
- 102100012125 NOTCH3 Human genes 0.000 claims 1
- 101710036045 NOTCH3 Proteins 0.000 claims 1
- 102100012124 NOTCH4 Human genes 0.000 claims 1
- 101710036039 NOTCH4 Proteins 0.000 claims 1
- 101700080605 NUC1 Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 108010008267 Nerve Growth Factors Proteins 0.000 claims 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 1
- 102100014784 PDCD6IP Human genes 0.000 claims 1
- 101710032431 PDCD6IP Proteins 0.000 claims 1
- 102100017157 PROM1 Human genes 0.000 claims 1
- 101700033975 PROM1 Proteins 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 102000020497 RNA-Binding Proteins Human genes 0.000 claims 1
- 108091022184 RNA-Binding Proteins Proteins 0.000 claims 1
- 230000004570 RNA-binding Effects 0.000 claims 1
- 102000035266 SCARB3 Human genes 0.000 claims 1
- 102100010587 SDC1 Human genes 0.000 claims 1
- 101700070405 SDC1 Proteins 0.000 claims 1
- 102100003569 SDCBP Human genes 0.000 claims 1
- 101710007997 SDCBP Proteins 0.000 claims 1
- 102100003578 SDCBP2 Human genes 0.000 claims 1
- 101710007996 SDCBP2 Proteins 0.000 claims 1
- 101710027453 SLC19A1 Proteins 0.000 claims 1
- 102100016008 SLIT2 Human genes 0.000 claims 1
- 101700045780 SLIT2 Proteins 0.000 claims 1
- 101700068918 STX3 Proteins 0.000 claims 1
- 102100002787 STX3 Human genes 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102100008904 TFRC Human genes 0.000 claims 1
- 101710036041 TFRC Proteins 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 102000033213 TRA Human genes 0.000 claims 1
- 101700050295 TRA Proteins 0.000 claims 1
- 101700078141 TRAC Proteins 0.000 claims 1
- 102000033158 TRB Human genes 0.000 claims 1
- 101710003153 TRB Proteins 0.000 claims 1
- 101710014372 TSPAN14 Proteins 0.000 claims 1
- 102100012538 TSPAN14 Human genes 0.000 claims 1
- 102100016885 TSPAN7 Human genes 0.000 claims 1
- 101710041050 TSPAN7 Proteins 0.000 claims 1
- 102100016880 TSPAN8 Human genes 0.000 claims 1
- 101710041051 TSPAN8 Proteins 0.000 claims 1
- 102000009332 Tetraspanins Human genes 0.000 claims 1
- 108050000196 Tetraspanins Proteins 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 101700029914 VTI11 Proteins 0.000 claims 1
- 101700032490 VTI12 Proteins 0.000 claims 1
- 101700081949 VTI1A Proteins 0.000 claims 1
- 102100002516 VTI1A Human genes 0.000 claims 1
- 101700017191 VTI1B Proteins 0.000 claims 1
- 102100009660 VTI1B Human genes 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 230000001580 bacterial Effects 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 101710036159 broA Proteins 0.000 claims 1
- 101710025091 cbbGC Proteins 0.000 claims 1
- 210000003850 cellular structures Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 101710025070 gapdh-2 Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 102000002467 interleukin receptors Human genes 0.000 claims 1
- 108010093036 interleukin receptors Proteins 0.000 claims 1
- 108010090909 laminin gamma 1 Proteins 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 101700006494 nucA Proteins 0.000 claims 1
- 108091013906 nucleotide binding proteins Proteins 0.000 claims 1
- 102000030264 nucleotide binding proteins Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 108090000464 transcription factors Proteins 0.000 claims 1
- 102000003995 transcription factors Human genes 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (15)
- (i)少なくとも1つの対象のポリペプチド(PoI);
(ii)少なくとも1つのエクソソームポリペプチド;及び
(iii)ポリペプチドに基づく放出系
を含む少なくとも1つのポリペプチド構築物を含む細胞外小胞(EV)であって、
前記ポリペプチドに基づく放出系が、内在的活性化により前記少なくとも1つのエクソソームポリペプチドから前記少なくとも1つのPoIを放出し、
前記ポリペプチドに基づく放出系が、シス切断性放出系又は核局在化シグナル(NLS)-核局在化シグナル結合タンパク質(NLSBP)(NLS-NLSBP)放出系から選択される、
EV。 - 前記PoIが、抗体、細胞内抗体、一本鎖可変断片、アフィボディ、酵素、腫瘍抑制剤、ウイルス又は細菌阻害剤、細胞成分タンパク質、DNA及び/又はRNA結合タンパク質、DNA修復阻害剤、ヌクレアーゼ、プロテイナーゼ、インテグラーゼ、転写因子、成長因子、アポトーシス阻害剤及び誘導物質、毒素、構造タンパク質、神経栄養因子、膜輸送体、ヌクレオチド結合タンパク質、熱ショックタンパク質、CRISPR関連タンパク質、並びにその任意の組合せを含む群から選択される治療的ポリペプチドである、請求項1に記載のEV。
- 前記エクソソームポリペプチドが、CD9、CD53、CD63、CD81、CD54、CD50、FLOT1、FLOT2、CD49d、CD71、CD133、CD138、CD235a、ALIX、シンテニン-1、シンテニン-2、Lamp2b、TSPAN8、TSPAN14、CD37、CD82、CD151、CD231、CD102、NOTCH1、NOTCH2、NOTCH3、NOTCH4、DLL1、DLL4、JAG1、JAG2、CD49d/ITGA4、ITGB5、ITGB6、ITGB7、CD11a、CD11b、CD11c、CD18/ITGB2、CD41、CD49b、CD49c、CD49e、CD51、CD61、CD104、テトラスパニン、Fc受容体、インターロイキン受容体、免疫グロブリン、MHC-I又はMHC-II成分、CD2、CD3ε、CD3ζ、CD13、CD18、CD19、CD30、CD34、CD36、CD40、CD40L、CD44、CD45、CD45RA、CD47、CD86、CD110、CD111、CD115、CD117、CD125、CD135、CD184、CD200、CD279、CD273、CD274、CD362、COL6A1、AGRN、EGFR、GAPDH、GLUR2、GLUR3、HLA-DM、HSPG2、L1CAM、LAMB1、LAMC1、LFA-1、LGALS3BP、Mac-1α、Mac-1β、MFGE8、SLIT2、STX3、TCRA、TCRB、TCRD、TCRG、VTI1A、VTI1B、及び他のエクソソームポリペプチドを含む群から選択される、請求項1又は2に記載のEV。
- 前記EVが、少なくとも1つの対象のポリヌクレオチドを更に含む、請求項1から3のいずれか一項に記載のEV。
- 前記対象のポリヌクレオチドが、RNA結合PoI又はDNA結合PoIとの相互作用によって前記EVに輸送される、請求項4に記載のEV。
- 少なくとも1つのPoIを含むEVであって、前記PoIが、ポリペプチドに基づく放出系の内在的活性化によって少なくとも1つのエクソソームポリペプチドから放出されたものである、EV。
- 前記EVが、対象のポリヌクレオチドを更に含む、請求項6に記載のEV。
- 前記EVが、少なくとも1つの標的化部分を更に含む、請求項1から7のいずれか一項に記載のEV。
- 請求項1から8のいずれか一項に記載のEVを製造する方法であって、
i.少なくとも1つのPoI、内在的に活性化可能なポリペプチドに基づく放出系、及び少なくとも1つのエクソソームポリペプチドを含む少なくとも1つのポリペプチド構築物をコードする少なくとも1つのポリヌクレオチド構築物を、EV産生細胞に導入する工程;
ii.前記少なくとも1つのポリヌクレオチド構築物によりコードされる少なくとも1つのポリペプチド構築物を、前記EV産生細胞中で発現させる工程;並びに
iii.前記EV産生細胞からPoIを含むEVを回収する工程
を含む、方法。 - i.少なくとも1つのPoI;
ii.少なくとも1つの内在的に活性化可能なポリペプチドに基づく放出系であって、前記ポリペプチドに基づく放出系が、シス切断性放出系又は核局在化シグナル(NLS)-核局在化シグナル結合タンパク質(NLSBP)(NLS-NLSBP)放出系から選択される、放出系;及び
iii.少なくとも1つのエクソソームポリペプチド
をコードするポリヌクレオチド構築物。 - i.少なくとも1つのPoI;
ii.少なくとも1つの内在的に活性化可能なポリペプチドに基づく放出系であって、前記ポリペプチドに基づく放出系が、シス切断性放出系又は核局在化シグナル(NLS)-核局在化シグナル結合タンパク質(NLSBP)(NLS-NLSBP)放出系から選択される、放出系;及び
iii.少なくとも1つのエクソソームポリペプチド
を含むポリペプチド構築物。 - (i)少なくとも1つの請求項10に記載のポリヌクレオチド構築物、
(ii)少なくとも1つの請求項11に記載のポリペプチド構築物、及び/又は
(iii)少なくとも1つの請求項1〜8のいずれか一項に記載のEV
を含む細胞。 - 少なくとも1つのPoIの細胞内送達のためのin vitro方法であって、少なくとも1つの請求項1〜8のいずれか一項に記載のEVと標的細胞とを接触させる工程を含む、方法。
- (i)少なくとも1つの請求項10に記載のポリヌクレオチド構築物、
(ii)少なくとも1つの請求項11に記載のポリペプチド構築物、
(iii)少なくとも1つの請求項1〜8のいずれか一項に記載のEV、及び/又は
(iv)請求項12に記載の細胞
を含む医薬組成物。 - 医薬に使用するための、請求項1〜8のいずれか一項に記載のEV及び/又はEVの集団を含む組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021042290A JP7483648B2 (ja) | 2016-05-25 | 2021-03-16 | 治療的ポリペプチドを含むエクソソーム |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1609216.5A GB201609216D0 (en) | 2016-05-25 | 2016-05-25 | Exosomes comprising therapeutic polypeptides |
GB1609216.5 | 2016-05-25 | ||
PCT/GB2017/051479 WO2017203260A1 (en) | 2016-05-25 | 2017-05-25 | Exosomes comprising therapeutic polypeptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021042290A Division JP7483648B2 (ja) | 2016-05-25 | 2021-03-16 | 治療的ポリペプチドを含むエクソソーム |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019520852A JP2019520852A (ja) | 2019-07-25 |
JP2019520852A5 true JP2019520852A5 (ja) | 2020-11-12 |
JP6855567B2 JP6855567B2 (ja) | 2021-04-07 |
Family
ID=56369954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019514870A Active JP6855567B2 (ja) | 2016-05-25 | 2017-05-25 | 治療的ポリペプチドを含むエクソソーム |
JP2021042290A Active JP7483648B2 (ja) | 2016-05-25 | 2021-03-16 | 治療的ポリペプチドを含むエクソソーム |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021042290A Active JP7483648B2 (ja) | 2016-05-25 | 2021-03-16 | 治療的ポリペプチドを含むエクソソーム |
Country Status (17)
Country | Link |
---|---|
US (2) | US11534499B2 (ja) |
EP (2) | EP3782646A1 (ja) |
JP (2) | JP6855567B2 (ja) |
KR (1) | KR102253731B1 (ja) |
CN (2) | CN109715211B (ja) |
AU (1) | AU2017270932B2 (ja) |
BR (1) | BR112018074229A2 (ja) |
CA (1) | CA3024020C (ja) |
DK (1) | DK3463465T3 (ja) |
ES (1) | ES2836553T3 (ja) |
GB (1) | GB201609216D0 (ja) |
MX (1) | MX2018014509A (ja) |
PT (1) | PT3463465T (ja) |
RU (1) | RU2737732C2 (ja) |
SG (1) | SG11201810116VA (ja) |
WO (1) | WO2017203260A1 (ja) |
ZA (1) | ZA201807945B (ja) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201609216D0 (en) | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
KR20220124817A (ko) | 2017-08-07 | 2022-09-14 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
GB2568255A (en) * | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
EP3781131A4 (en) * | 2018-04-19 | 2022-06-01 | Board of Regents, The University of Texas System | THERAPEUTIC MODULATION OF TUMOR SUPPRESSORS USING EXOSOMES |
CN108753806A (zh) * | 2018-06-20 | 2018-11-06 | 中国人民解放军第四军医大学 | 增强目标rna装载入外泌体的融合蛋白的表达载体及其构建方法和应用 |
CN108753822A (zh) * | 2018-06-20 | 2018-11-06 | 中国人民解放军第四军医大学 | 递送融合型rna结合蛋白的表达载体及其制备方法和应用 |
CN109293745A (zh) * | 2018-09-04 | 2019-02-01 | 暨南大学 | 一种运载蛋白、重组表达载体、外泌体及制备方法与应用 |
CN109321596B (zh) * | 2018-09-05 | 2021-12-17 | 暨南大学 | 一种包载蛋白的外泌体的制备方法与应用 |
CN109234237B (zh) * | 2018-09-30 | 2020-08-07 | 中国人民解放军第四军医大学 | 一种装载ABCA1 mRNA的外泌体及其构建方法和应用 |
SG11202103775PA (en) * | 2018-11-16 | 2021-05-28 | Evox Therapeutics Ltd | Extracellular vesicles for replacement of urea cycle proteins & nucleic acids |
WO2020152298A1 (en) * | 2019-01-24 | 2020-07-30 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Method for producing enzymes |
MX2021009337A (es) * | 2019-02-04 | 2021-10-13 | Codiak Biosciences Inc | Cadenas principales de proteínas de la membrana para la modificación genética de exosomas. |
US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
EP3986429A4 (en) * | 2019-06-21 | 2023-07-19 | Entelexo Biotherapeutics Inc. | PLATFORMS, COMPOSITIONS AND METHODS OF DELIVERING THERAPEUTIC COMPOUNDS |
KR102125567B1 (ko) * | 2019-07-02 | 2020-06-22 | 한양대학교 에리카산학협력단 | 식물 엑소좀의 대량 생산 방법 |
JPWO2021039884A1 (ja) * | 2019-08-28 | 2021-03-04 | ||
CN110954703A (zh) * | 2019-12-27 | 2020-04-03 | 杭州迪相实业有限公司 | 一种同时检测外泌体内蛋白和rna、外泌体膜蛋白的方法 |
CA3169228A1 (en) | 2020-02-05 | 2021-08-12 | Diadem Biotherapeutics Inc. | Artificial synapses |
US20230211010A1 (en) * | 2020-02-10 | 2023-07-06 | Exostemtech Co., Ltd. | Exosome comprising photocleavable protein, and use thereof |
CN115484990A (zh) | 2020-03-12 | 2022-12-16 | 基础科学研究院 | 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法 |
WO2021223659A1 (en) * | 2020-05-06 | 2021-11-11 | Nanjing Iaso Biotherapeutics Co., Ltd. | Extracellular vesicles targeting cancer cells and uses thereof |
CN111569077B (zh) * | 2020-05-29 | 2021-10-26 | 南方医科大学 | Flot2抑制剂在抑制破骨细胞形成和/或破骨活性中的应用 |
RU2766707C1 (ru) * | 2020-11-13 | 2022-03-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный университет имени М.В.Ломоносова» (МГУ) | Средство для лечения фиброза тканей на основе компонентов секретома мезенхимных стромальных клеток, способ получения и применения средства |
CN112773775B (zh) * | 2021-01-13 | 2022-12-20 | 广东药科大学 | 一种负载去甲斑蝥素外泌体的制备方法及其应用 |
WO2022158836A1 (ko) * | 2021-01-21 | 2022-07-28 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
WO2022215078A1 (en) * | 2021-04-07 | 2022-10-13 | Ramot At Tel-Aviv University Ltd. | Modified cannabinoids and uses thereof |
WO2022214522A2 (en) | 2021-04-07 | 2022-10-13 | Astrazeneca Ab | Compositions and methods for site-specific modification |
JP2024514671A (ja) * | 2021-04-22 | 2024-04-02 | オハイオ・ステイト・イノベーション・ファウンデーション | 腫瘍関連マクロファージを標的とするためのナノキャリア |
GB202107182D0 (en) * | 2021-05-19 | 2021-06-30 | Evox Therapeutics Ltd | Nanoparticle delivery system for production of engineered extracellular vesicles |
EP4357611A1 (en) | 2021-06-16 | 2024-04-24 | NSK Ltd. | Load estimating device for rolling bearing, control device for mechanical device provided with rolling bearing, load estimating method, and program |
AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
JPWO2023058691A1 (ja) | 2021-10-07 | 2023-04-13 | ||
WO2023102550A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
GB202211033D0 (en) * | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
CN116803424B (zh) * | 2023-08-24 | 2023-11-28 | 上海懿贝瑞生物医药科技有限公司 | Slc17a5基因抑制剂及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834247A (en) * | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
US5935822A (en) | 1995-03-21 | 1999-08-10 | The Regents Of The University Of Colorado | Product and process for membrane and soluble polypeptide segregation |
GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
CN104356225B (zh) | 2007-08-20 | 2018-02-13 | 肿瘤疗法科学股份有限公司 | Cdh3 肽以及含有cdh3 肽的药剂 |
EP4032899A1 (en) | 2007-08-20 | 2022-07-27 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
EP2127640A1 (en) | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Azide modified proteins |
GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
CN103205435A (zh) | 2013-04-11 | 2013-07-17 | 浙江大学 | 利用内含肽系统大肠杆菌表达乳铁蛋白改良肽lf-6的方法 |
US11274139B2 (en) * | 2013-04-12 | 2022-03-15 | Evox Therapeutics Ltd | Therapeutic delivery vesicles |
CA2905229C (en) * | 2013-06-11 | 2023-10-10 | Clontech Laboratories, Inc. | Protein enriched microvesicles and methods of making and using the same |
WO2015002956A1 (en) | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
US10370420B2 (en) | 2014-02-11 | 2019-08-06 | The Governors Of The University Of Alberta | Genetically encoded photocleavable proteins |
US20170173113A1 (en) | 2014-03-13 | 2017-06-22 | Research Institute At Nationwide Children's Hospital | Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes |
WO2016077639A2 (en) * | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
WO2016178532A1 (ko) * | 2015-05-04 | 2016-11-10 | 한국과학기술원 | 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법 |
GB201609216D0 (en) | 2016-05-25 | 2016-07-06 | Evox Therapeutics And Isis Innovation Ltd | Exosomes comprising therapeutic polypeptides |
-
2016
- 2016-05-25 GB GBGB1609216.5A patent/GB201609216D0/en not_active Ceased
-
2017
- 2017-05-25 WO PCT/GB2017/051479 patent/WO2017203260A1/en unknown
- 2017-05-25 MX MX2018014509A patent/MX2018014509A/es unknown
- 2017-05-25 RU RU2018145738A patent/RU2737732C2/ru active
- 2017-05-25 EP EP20201528.5A patent/EP3782646A1/en active Pending
- 2017-05-25 PT PT177273257T patent/PT3463465T/pt unknown
- 2017-05-25 US US16/304,580 patent/US11534499B2/en active Active
- 2017-05-25 EP EP17727325.7A patent/EP3463465B1/en active Active
- 2017-05-25 BR BR112018074229-5A patent/BR112018074229A2/pt not_active Application Discontinuation
- 2017-05-25 JP JP2019514870A patent/JP6855567B2/ja active Active
- 2017-05-25 AU AU2017270932A patent/AU2017270932B2/en active Active
- 2017-05-25 DK DK17727325.7T patent/DK3463465T3/da active
- 2017-05-25 KR KR1020187037527A patent/KR102253731B1/ko active IP Right Grant
- 2017-05-25 CA CA3024020A patent/CA3024020C/en active Active
- 2017-05-25 ES ES17727325T patent/ES2836553T3/es active Active
- 2017-05-25 SG SG11201810116VA patent/SG11201810116VA/en unknown
- 2017-05-25 CN CN201780046456.3A patent/CN109715211B/zh active Active
- 2017-05-25 CN CN202211545146.5A patent/CN116103241A/zh active Pending
-
2018
- 2018-11-23 ZA ZA2018/07945A patent/ZA201807945B/en unknown
-
2021
- 2021-03-16 JP JP2021042290A patent/JP7483648B2/ja active Active
-
2022
- 2022-11-21 US US18/057,359 patent/US20230201370A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019520852A5 (ja) | ||
RU2018145738A (ru) | Экзосомы, содержащие терапевтические полипептиды | |
RU2020118554A (ru) | Экзосомы, содержащие рнк-терапевтические средства | |
JP2021507682A5 (ja) | ||
JP2019524745A5 (ja) | ||
JP7091447B2 (ja) | 新型なscFvアミノ酸配列、それを含むキメラ抗原受容体、およびその使用 | |
Denkberg et al. | Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen | |
JP2018528786A5 (ja) | ||
JP7038353B2 (ja) | エクスビボのbite活性化t細胞 | |
RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
JP2021502105A5 (ja) | ||
AU2021232753A1 (en) | T cell recruiting polypeptides based on TCR alpha/beta reactivity | |
JP2018529327A5 (ja) | ||
JP2010535032A5 (ja) | ||
JPWO2019173324A5 (ja) | ||
CN110655581B (zh) | 一种抗癌胚抗原的抗体及其制备方法和用途 | |
CN113416248B (zh) | 一种纳米抗体及其应用 | |
CN108530538A (zh) | EpCAM单域抗体E6 | |
JPWO2020071554A5 (ja) | ||
JP2017536821A5 (ja) | ||
CN106928355B (zh) | 一种CD105纳米抗体Nb184 | |
CN106928368B (zh) | 一种FAP纳米抗体Nb57 | |
JP2023516089A (ja) | がんの治療のための組成物及び方法 | |
CN107880127B (zh) | 全人源抗pdl-1单链抗体b129及其应用 |